Thomas Cerny
Swissmedic(CH)
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, Lung Cancer Treatments and Mutations, Global Cancer Incidence and Screening, Complementary and Alternative Medicine Studies, Chronic Lymphocytic Leukemia Research
Most-Cited Works
- → Multiple primary tumours: challenges and approaches, a review(2017)609 cited
- → Mediastinal Lymph Node Clearance After Docetaxel-Cisplatin Neoadjuvant Chemotherapy Is Prognostic of Survival in Patients With Stage IIIA pN2 Non–Small-Cell Lung Cancer: A Multicenter Phase II Trial(2003)453 cited
- → Mechanism of action of rituximab(2002)290 cited
- → A Vaccine against Nicotine for Smoking Cessation: A Randomized Controlled Trial(2008)282 cited
- → Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98(2010)241 cited
- → Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study(2006)207 cited
- → Effect of Single-Agent Rituximab Given at the Standard Schedule or As Prolonged Treatment in Patients With Mantle Cell Lymphoma: A Study of the Swiss Group for Clinical Cancer Research (SAKK)(2004)197 cited
- → Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer(2011)192 cited
- → A Bayesian generalized age–period–cohort power model for cancer projections(2014)165 cited
- → Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK)(2005)161 cited